Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Randomized, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 mg as Compared to Amlodipine/Valsartan 5/40 mg or to Amlodipine 5 mg Once Daily in Elderly Patients With Essential Hypertension Not Adequately Controlled After Four Weeks on Amlodipine 5 mg Once Daily
Conditions
Interventions
Amlodipine 5 mg
Valsartan 80 mg
+2 more
Locations
18
Czechia
Novartis Investigative site
Brno, Czechia
Investigative site Czech Republic
Chrudim, Czechia
Investigative sites Czech Repbulic
Hodonín, Czechia
Investigative site Czech Repbulic
Jičín, Czechia
Sites in Czech Republic
Náchod, Czechia
Investigative sites Czech Republic
Prague, Czechia
Start Date
May 1, 2008
Primary Completion Date
May 1, 2009
Completion Date
May 1, 2009
Last Updated
June 6, 2011
NCT02417740
NCT07480265
NCT07073820
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions